Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Part of paid clinical trials in Louisville, Kentucky.

Sponsor
University of Louisville
Study ID
NCT03080974
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
  • Irreversible Electroporation — PROCEDURE
    Non-thermal ablation of tumor

Study Details

Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.

Key Dates

Start date
Aug 14, 2017
Status verified
Oct 2025
Primary completion
Jun 1, 2028
Completion
Apr 1, 2029

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm
    All patients undergoing irreversible electroporation will be treated with nivolumab

Primary Outcome Measure

Safety and Tolerability of Combination Irreversible Electroporation and Nivolumab Treatment [ Time Frame: Baseline thru 100 days after receiving last dose ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of LouisvilleLouisvilleKentucky40202-

Find similar trials in Louisville, KY

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
University of Louisville· Louisville, KY

Related Studies